40 related articles for article (PubMed ID: 12479219)
1. Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin.
Fan D; Yano S; Shinohara H; Solorzano C; Van Arsdall M; Bucana CD; Pathak S; Kruzel E; Herbst RS; Onn A; Roach JS; Onda M; Wang QC; Pastan I; Fidler IJ
Mol Cancer Ther; 2002 Jun; 1(8):595-600. PubMed ID: 12479219
[TBL] [Abstract][Full Text] [Related]
2. A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells.
Wolf P; Gierschner D; Bühler P; Wetterauer U; Elsässer-Beile U
Cancer Immunol Immunother; 2006 Nov; 55(11):1367-73. PubMed ID: 16547705
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers.
Skorupan N; Peer CJ; Zhang X; Choo-Wosoba H; Ahmad MI; Lee MJ; Rastogi S; Sato N; Yu Y; Pegna GJ; Steinberg SM; Kalsi SS; Cao L; Figg WD; Trepel JB; Pastan I; FitzGerald D; Alewine C
Front Oncol; 2024; 14():1386190. PubMed ID: 38706610
[TBL] [Abstract][Full Text] [Related]
4. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.
Golfier S; Kopitz C; Kahnert A; Heisler I; Schatz CA; Stelte-Ludwig B; Mayer-Bartschmid A; Unterschemmann K; Bruder S; Linden L; Harrenga A; Hauff P; Scholle FD; Müller-Tiemann B; Kreft B; Ziegelbauer K
Mol Cancer Ther; 2014 Jun; 13(6):1537-48. PubMed ID: 24714131
[TBL] [Abstract][Full Text] [Related]
5. Mesothelin expression in human lung cancer.
Ho M; Bera TK; Willingham MC; Onda M; Hassan R; FitzGerald D; Pastan I
Clin Cancer Res; 2007 Mar; 13(5):1571-5. PubMed ID: 17332303
[TBL] [Abstract][Full Text] [Related]
6. A tri-specific killer engager against mesothelin targets NK cells towards lung cancer.
Kennedy PR; Vallera DA; Ettestad B; Hallstrom C; Kodal B; Todhunter DA; Bendzick L; Hinderlie P; Walker JT; Pulkrabek B; Pastan I; Kratzke RA; Fujioka N; Miller JS; Felices M
Front Immunol; 2023; 14():1060905. PubMed ID: 36911670
[TBL] [Abstract][Full Text] [Related]
7. Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis.
Qin L; Cui Y; Yuan T; Chen D; Zhao R; Li S; Jiang Z; Wu Q; Long Y; Wang S; Tang Z; Pan H; Li X; Wei W; Yang J; Luo X; Zhang Z; Tang Q; Liu P; Weinkove R; Yao Y; Qin D; Thiery JP; Li P
Nat Commun; 2022 Oct; 13(1):6051. PubMed ID: 36229619
[TBL] [Abstract][Full Text] [Related]
8.
Havaei SM; Aucoin MG; Jahanian-Najafabadi A
Front Oncol; 2021; 11():781800. PubMed ID: 34976821
[TBL] [Abstract][Full Text] [Related]
9. HOX transcription factors are potential targets and markers in malignant mesothelioma.
Morgan R; Simpson G; Gray S; Gillett C; Tabi Z; Spicer J; Harrington KJ; Pandha HS
BMC Cancer; 2016 Feb; 16():85. PubMed ID: 26867567
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for non-small cell lung cancer: current concepts and clinical trials.
Mayor M; Yang N; Sterman D; Jones DR; Adusumilli PS
Eur J Cardiothorac Surg; 2016 May; 49(5):1324-33. PubMed ID: 26516195
[TBL] [Abstract][Full Text] [Related]
11. Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival.
Tozbikian G; Brogi E; Kadota K; Catalano J; Akram M; Patil S; Ho AY; Reis-Filho JS; Weigelt B; Norton L; Adusumilli PS; Wen HY
PLoS One; 2014; 9(12):e114900. PubMed ID: 25506917
[TBL] [Abstract][Full Text] [Related]
12. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.
Maus MV; Haas AR; Beatty GL; Albelda SM; Levine BL; Liu X; Zhao Y; Kalos M; June CH
Cancer Immunol Res; 2013 Jul; 1(1):26-31. PubMed ID: 24777247
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mesothelin as a novel strategy for targeting cancer cells.
Wang K; Bodempudi V; Liu Z; Borrego-Diaz E; Yamoutpoor F; Meyer A; Woo RA; Pan W; Dudek AZ; Olyaee MS; Esfandyari T; Farassati F
PLoS One; 2012; 7(4):e33214. PubMed ID: 22485139
[TBL] [Abstract][Full Text] [Related]
14. Bacteria in cancer therapy: a novel experimental strategy.
Patyar S; Joshi R; Byrav DS; Prakash A; Medhi B; Das BK
J Biomed Sci; 2010 Mar; 17(1):21. PubMed ID: 20331869
[TBL] [Abstract][Full Text] [Related]
15. A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model.
Gattenlöhner S; Jörissen H; Huhn M; Vincent A; Beeson D; Tzartos S; Mamalaki A; Etschmann B; Muller-Hermelink HK; Koscielniak E; Barth S; Marx A
J Biomed Biotechnol; 2010; 2010():187621. PubMed ID: 20204062
[TBL] [Abstract][Full Text] [Related]
16. High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma.
Cheng WF; Huang CY; Chang MC; Hu YH; Chiang YC; Chen YL; Hsieh CY; Chen CA
Br J Cancer; 2009 Apr; 100(7):1144-53. PubMed ID: 19293794
[TBL] [Abstract][Full Text] [Related]
17. Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy.
Alvarez H; Rojas PL; Yong KT; Ding H; Xu G; Prasad PN; Wang J; Canto M; Eshleman JR; Montgomery EA; Maitra A
Nanomedicine; 2008 Dec; 4(4):295-301. PubMed ID: 18691948
[TBL] [Abstract][Full Text] [Related]
18. Immunotoxins for targeted cancer therapy.
Kreitman RJ
AAPS J; 2006 Aug; 8(3):E532-51. PubMed ID: 17025272
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel human CTL epitopes and their agonist epitopes of mesothelin.
Yokokawa J; Palena C; Arlen P; Hassan R; Ho M; Pastan I; Schlom J; Tsang KY
Clin Cancer Res; 2005 Sep; 11(17):6342-51. PubMed ID: 16144939
[TBL] [Abstract][Full Text] [Related]
20. Gene overexpression in pancreatic adenocarcinoma: diagnostic and therapeutic implications.
Rodriguez JA; Li M; Yao Q; Chen C; Fisher WE
World J Surg; 2005 Mar; 29(3):297-305. PubMed ID: 15696394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]